BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Santopaolo F, Lenci I, Milana M, Manzia TM, Baiocchi L. Liver transplantation for hepatocellular carcinoma: Where do we stand? World J Gastroenterol 2019; 25(21): 2591-2602 [PMID: 31210712 DOI: 10.3748/wjg.v25.i21.2591] [Cited by in CrossRef: 22] [Cited by in F6Publishing: 18] [Article Influence: 7.3] [Reference Citation Analysis]
Number Citing Articles
1 Wei J, Ye L, Song L, Tang H, Zhang T, Fu B, Zhang Y, Yang Q, Yang Y, Yi S. TSC1/2 mutations-a unique type of mutation suitable for liver transplantation of Hepatocellular carcinoma. J Gastrointest Oncol 2021;12:1074-85. [PMID: 34295558 DOI: 10.21037/jgo-20-378] [Reference Citation Analysis]
2 Dolicka D, Foti M, Sobolewski C. The Emerging Role of Stress Granules in Hepatocellular Carcinoma. Int J Mol Sci 2021;22:9428. [PMID: 34502337 DOI: 10.3390/ijms22179428] [Reference Citation Analysis]
3 Manzia TM, Angelico R, Gazia C, Lenci I, Milana M, Ademoyero OT, Pedini D, Toti L, Spada M, Tisone G, Baiocchi L. De novo malignancies after liver transplantation: The effect of immunosuppression-personal data and review of literature. World J Gastroenterol 2019; 25(35): 5356-5375 [PMID: 31558879 DOI: 10.3748/wjg.v25.i35.5356] [Cited by in CrossRef: 19] [Cited by in F6Publishing: 14] [Article Influence: 6.3] [Reference Citation Analysis]
4 Bosma PJ, Wits M, Oude-Elferink RP. Gene Therapy for Progressive Familial Intrahepatic Cholestasis: Current Progress and Future Prospects. Int J Mol Sci 2020;22:E273. [PMID: 33383947 DOI: 10.3390/ijms22010273] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
5 Chairi MHM, González MM, Alonso AJP, Bastante MD, De Los Ángles Herrero Torres M, Gallardo CA, Jiménez AP. Liver Transplantation in Patients With Hepatocellular Carcinoma: Long-Term Survival Results. Transplant Proc 2021:S0041-1345(21)00814-9. [PMID: 34895899 DOI: 10.1016/j.transproceed.2021.09.065] [Reference Citation Analysis]
6 Villalobos A, Wagstaff W, Guo M, Zhang J, Bercu Z, Whitmore MJ, Cristescu MM, Majdalany BS, Wedd J, Akce M, Magliocca J, Kokabi N. Predictors of Successful Yttrium-90 Radioembolization Bridging or Downstaging in Patients with Hepatocellular Carcinoma. Can J Gastroenterol Hepatol 2021;2021:9926704. [PMID: 34336728 DOI: 10.1155/2021/9926704] [Reference Citation Analysis]
7 Ivanics T, Shwaartz C, Claasen MPAW, Patel MS, Yoon P, Raschzok N, Wallace D, Muaddi H, Murillo Perez CF, Hansen BE, Selzner N, Sapisochin G. Trends in indications and outcomes of liver transplantation in Canada: A multicenter retrospective study. Transpl Int 2021;34:1444-54. [PMID: 33977568 DOI: 10.1111/tri.13903] [Reference Citation Analysis]
8 Lozanovski VJ, Ramouz A, Aminizadeh E, Al-Saegh SA, Khajeh E, Probst H, Picardi S, Rupp C, Chang DH, Probst P, Mehrabi A. Prognostic role of selection criteria for liver transplantation in patients with hepatocellular carcinoma: a network meta-analysis. BJS Open 2022;6:zrab130. [PMID: 35211739 DOI: 10.1093/bjsopen/zrab130] [Reference Citation Analysis]
9 Cui M, Qu F, Wang L, Liu X, Yu J, Tang Z, Cheng D. m5C RNA methyltransferase-related gene NSUN4 stimulates malignant progression of hepatocellular carcinoma and can be a prognostic marker. Cancer Biomark 2021. [PMID: 34744073 DOI: 10.3233/CBM-210154] [Reference Citation Analysis]
10 Wong MM, Chan HY, Aziz NA, Ramasamy TS, Bong JJ, Ch'ng ES, Armon S, Peh SC, Teow SY. Interplay of autophagy and cancer stem cells in hepatocellular carcinoma. Mol Biol Rep 2021;48:3695-717. [PMID: 33893928 DOI: 10.1007/s11033-021-06334-9] [Reference Citation Analysis]
11 Casler K, Chaney A. Cirrhosis: An evidence-based approach. Nursing 2021;51:24-34. [PMID: 33953095 DOI: 10.1097/01.NURSE.0000731828.24893.bb] [Reference Citation Analysis]
12 Tan DJH, Wong C, Ng CH, Poh CW, Jain SR, Huang DQ, Muthiah MD. A Meta-Analysis on the Rate of Hepatocellular Carcinoma Recurrence after Liver Transplant and Associations to Etiology, Alpha-Fetoprotein, Income and Ethnicity. J Clin Med 2021;10:E238. [PMID: 33440759 DOI: 10.3390/jcm10020238] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
13 Zhang S, Chen ZW, Meng SM, Ding QL, Zhong ZB, Wei YH, Ye QF, Hu KH. Eukaryotic initiation factor 3e subunit is positively associated with tumorigenesis and development of hepatocellular carcinoma. Shijie Huaren Xiaohua Zazhi 2020; 28(12): 475-485 [DOI: 10.11569/wcjd.v28.i12.475] [Reference Citation Analysis]
14 Almeida PH, Matielo CEL, Curvelo LA, Rocco RA, Felga G, Della Guardia B, Boteon YL. Update on the management and treatment of viral hepatitis. World J Gastroenterol 2021; 27(23): 3249-3261 [PMID: 34163109 DOI: 10.3748/wjg.v27.i23.3249] [Reference Citation Analysis]
15 Liu H, Cheng J, Xu H, Wan Z. Lidocaine has antitumor effect on hepatocellular carcinoma via the circ_DYNC1H1/miR-520a-3p/USP14 axis. Open Life Sci 2021;16:766-80. [PMID: 34435133 DOI: 10.1515/biol-2021-0072] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
16 Ersan V, Barut B, Yilmaz S. The Timing of Liver Transplantation Following Downstaging: Wait of Not to Wait? J Gastrointest Cancer 2020;51:1152-6. [PMID: 32856230 DOI: 10.1007/s12029-020-00491-z] [Reference Citation Analysis]
17 Kim J, Zimmerman MA, Hong JC. Liver transplantation in the treatment of unresectable hepatic metastasis from neuroendocrine tumors. J Gastrointest Oncol. 2020;11:601-608. [PMID: 32655939 DOI: 10.21037/jgo.2019.11.03] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
18 Azhie A, Grant RC, Herman M, Wang L, Knox JJ, Bhat M. Phase II clinical trial of cabozantinib for the treatment of recurrent hepatocellular carcinoma after liver transplantation. Future Oncol 2022. [PMID: 35287469 DOI: 10.2217/fon-2021-1635] [Reference Citation Analysis]
19 Kim P, Littau M, Baker TB, Abdelsattar Z, Tonelli C, Bunn C, Kulshrestha S, Luchette FA, Baker MS. Intrahepatic cholangiocarcinoma: Is there a role for liver transplantation? Surgery 2021:S0039-6060(21)00989-2. [PMID: 34895770 DOI: 10.1016/j.surg.2021.09.034] [Reference Citation Analysis]
20 Sarno G, Montalti R, Giglio MC, Rompianesi G, Tomassini F, Scarpellini E, De Simone G, De Palma GD, Troisi RI. Hepatocellular carcinoma in patients with chronic renal disease: Challenges of interventional treatment. Surg Oncol 2021;36:42-50. [PMID: 33307490 DOI: 10.1016/j.suronc.2020.11.007] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
21 Heimbach JK. Evolution of Liver Transplant Selection Criteria and U.S. Allocation Policy for Patients with Hepatocellular Carcinoma. Semin Liver Dis 2020;40:358-64. [PMID: 32942324 DOI: 10.1055/s-0040-1709492] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
22 Duan Y, Meng Y, Gao Z, Wang X, Zhang H. microRNA-9-5p protects liver sinusoidal endothelial cell against oxygen glucose deprivation/reperfusion injury. Open Life Sci 2021;16:375-83. [PMID: 33977146 DOI: 10.1515/biol-2021-0042] [Reference Citation Analysis]
23 He JJ, Shang L, Yu QW, Jiao N, Qiu S, Zhu WX, Wu DF, Tian YE, Zhang Q. High expression of protein phosphatase 2 regulatory subunit B'' alpha predicts poor outcome in hepatocellular carcinoma patients after liver transplantation. World J Gastrointest Oncol 2021; 13(7): 716-731 [PMID: 34322200 DOI: 10.4251/wjgo.v13.i7.716] [Reference Citation Analysis]
24 Liu L, Liang X, Xu X, Zhang X, Wen J, Chen K, Su X, Teng Z, Lu G, Xu J. Magnetic mesoporous embolic microspheres in transcatheter arterial chemoembolization for liver cancer. Acta Biomater 2021;130:374-84. [PMID: 34082098 DOI: 10.1016/j.actbio.2021.05.031] [Reference Citation Analysis]
25 Yang Z, Wang S, Tian XY, Xie QF, Zhuang L, Li QY, Chen CZ, Zheng SS. Impact of treatment modalities on patients with recurrent hepatocellular carcinoma after liver transplantation: Preliminary experience. Hepatobiliary Pancreat Dis Int 2020;19:365-70. [PMID: 32553774 DOI: 10.1016/j.hbpd.2020.06.002] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]